Reprogramming T cell differentiation and exhaustion in CAR-T cell therapy.

"Declarations Ethics approval and consent to participateNot applicable. Consent for publicationThe authors permit the Journal of Hematology and Oncology to publish this work. Competing interestsA.M.T declares receipt of clinical trial research funding (to The University of Texas MD Anderson Cancer Center) from OBI Pharma, Agenus, IMMATICS, Tachyon, Novocure, Parker Institute for Cancer Immunotherapy, Orionis, Tempus, and Tvardi; fees for consulting; or advisory roles for Avstera Therapeutics, Bioeclipse, BrYet, Diaccurate, Macrogenics, NEX-I and VinceRx. Y.B is Employee of Appia Bio. J.D is Employee of Appia Bio. The remaining authors declare no relevant conflict of interest. Competing interests A.M.T declares receipt of clinical trial research funding (to The University of Texas MD Anderson Cancer Center) from OBI Pharma, Agenus, IMMATICS, Tachyon, Novocure, Parker Institute for Cancer Immunotherapy, Orionis, Tempus, and Tvardi; fees for consulting; or advisory roles for Avstera Therapeutics, Bioeclipse, BrYet, Diaccurate, Macrogenics, NEX-I and VinceRx. Y.B is Employee of Appia Bio. J.D is Employee of Appia Bio. The remaining authors declare no relevant conflict of interest."

"Funding This work was supported in part by the National Institutes of Health/National Cancer Institute award number P30 CA016672 (University of Texas MD Anderson Cancer Center). This work was also supported by Mr. and Mrs. Steven Mckenzie’s Endowment and donor funds from Jamie’s Hope and Mrs. and Mr. James Ritter for Dr. Tsimberidou’s Personalized Medicine Program (Initiative for Molecular Profiling and Advanced Cancer Therapy, IMPACT)."